Congressman with $11.5 Million in Trades Keeps Selling Stocks: Here’s the Latest Moves
A member of Congress continues to sell stocks, with no buys since 2024. Here are the latest names traded.
Stocks · News reference
AbbVie Receives European Commission Approval Of RINVOQ For Children With Active Polyarticular Juvenile Idiopathic Arthritis Aged Two And Older
RINVOQ is now approved in the European Union for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients two years of age and older who have responded inadequately to, or who are
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
AbbVie's Allergan Aesthetics Announces U.S. Launch Of AA Signature Consultation Program
AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September?
The article compares two pharmaceutical dividend stocks: AbbVie and Pfizer. AbbVie is a Dividend King with 50+ consecutive years of dividend increases, offering a 2.6% yield and $18 billion in free cash flow, with strong growth from immunology products like Rinvoq and Skyrizi. Pfizer is in recovery mode post-pandemic, offering a higher 6.2% dividend yield but with less consistent growth. The author recommends AbbVie as the better dividend buy due to its proven ability to grow dividends sustainably and demonstrated business resilience after losing Humira exclusivity.